The Food and Drug Administration (FDA) has expanded the approval of Evkeeza ® (evinacumab-dgnb) to include children aged 1 year and older with homozygous familial hypercholesterolemia (HoFH).

The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington ...

HealthDay News — The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the European Association for the Study of ...

HealthDay News — Psilocybin-assisted therapy (PAT) shows long-term safety and efficacy for treating symptoms of major depressive disorder (MDD), according to a study published online September 4 in ...

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.

HealthDay News — During August 2021 to August 2023, only 36.4% of US adults had no cardiovascular disease (CVD) risk factors, according to a September data brief published by the National Center for ...

Up to 32% lower risk conferred by early initiation, while increased risk for dementia seen in studies among older women.

HealthDay News — Cocoa extract supplementation yields a significant reduction in high-sensitivity C-reactive protein (hsCRP) and an increase in interferon-γ (IFN-γ), while no significant effects are ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...

Cesium-137 is a man-made radioactive element sometimes found in contaminated soil, water or food, and has been linked to cancer.

HealthDay News — Costco has recalled more than 3000 pounds of its Kirkland Signature Ahi Tuna Wasabi Poke after testing found a risk of listeria contamination.

A phase 1/2 study is currently underway to evaluate SAR446268 in participants aged 10 to 50 years with non-congenital myotonic dystrophy type 1.